THERAPEUTICS

Adding psychosocial therapy to methylphenidate may not improve its effectiveness in stimulant responsive children with ADHD


Q Does adding psychosocial therapy to methylphenidate improve effectiveness of treatment for ADHD in stimulant responsive children?

METHODS

- Design: Randomised controlled trial.
- Allocation: Not reported.
- Blinding: Phase 1 unblinded; phase 2 participants blinded to placebo substitution.
- Follow up period: 24 months.
- Setting: Two medical centres, New York and Montreal.

Patients: 103 children aged 7-10 years with DSM-III attention deficit/hyperactivity disorder (ADHD) who had previously responded to methylphenidate; ≥1.5 on hyperactivity index of Conners’ teacher rating scale; medication free for at least two weeks before evaluation. Main exclusions: concomitant neurological disorder; psychosis; significant medical illness; tic or Tourette’s disorder; developmental, conduct, and learning disorders; physical or sexual abuse.

Intervention: Phase 1: methylphenidate alone (M; n = 34), methylphenidate + multimodal psychosocial treatment (M + MPT; n = 34) and methylphenidate + attention control psychosocial treatment (M + ACT; n = 35) for 1 year. All participants received individually tailored methylphenidate regimens. Phase 2: after 1 year, methylphenidate was substituted for placebo and psychosocial treatments were continued as initially allocated. MPT involved family therapy, academic training, assistance and remediation, social skills training, and individual psychotherapy. ACT excluded specific remedial or therapeutic content. MPT and ACT were delivered weekly in phase 1 and monthly in phase 2.

Outcomes: Hyperkinesis Index of Conners’ parent rating scale; Conners’ teacher rating scale; ADHD (DSM-III), oppositional defiant disorder (ODD) symptoms are a plausible candidate for measuring the additive effects of MPT. However, only half of the study subjects met criteria for ODD. In addition, measures of ODD symptoms (clinician rated symptom count and the number of subjects moving from case to non-case in each group) did not capture the full dimensional range of severity.

Patient follow up: 80% of children completed the study.

MAIN RESULTS

The paper did not present between group comparisons at the end of phase 1. However, it concluded that there was no difference between treatments (see notes). In phase 2, after placebo substitution of methylphenidate, added MPT increased time to relapse compared with added ACT or no added psychosocial treatment, although results were not significant at the predefined 0.01 level (mean time to relapse: 8.6 days with M alone; 11.7 with M + ACT; 17.1 with M + MPT; p<0.04 for M + MPT versus M).

CONCLUSIONS

There is no benefit from adding psychosocial treatment to methylphenidate in stimulant responsive children with ADHD.

NOTES

Conclusions are limited by small sample size, so it is not possible to exclude clinically important effects of psychosocial treatment. Absolute results appeared to differ considerably among groups for some outcomes, but were not statistically compared (for example, prevalence of ADHD at 12 months varied from 6.5% to 16.7%). The significance level was corrected to p = 0.01 for multiple analyses. Treatments were randomly allocated in blocks comprising four participants, so that group psychosocial treatment could be conducted.

Commentary

This National Institute of Mental Health sponsored study is a valuable contribution to the field. Children (n=103; age 7–9 years) were randomly assigned to methylphenidate only (M), methylphenidate plus multimodal psychosocial treatment (M + MPT), or methylphenidate plus attention control psychosocial treatment (M + ACT). Before randomisation, all subjects showed a positive response to M in a five week open label trial. Multiple outcomes were assessed every six months for two years.

The paper did not specify a primary outcome measure. After six months, the effect size of M was 1.4 on the parent rated Conners’ Hyperactivity Index scale and 2.5 on the teacher rated Conners’ Hyperactivity scale. These large effects leave little room to detect additive effects of MPT on ADHD outcomes. Oppositional defiant disorder (ODD) symptoms are a plausible candidate for measuring the additive effects of MPT. However, only half of the study subjects met criteria for ODD. In addition, measures of ODD symptoms (clinician rated symptom count and the number of subjects moving from case to non-case in each group) did not capture the full dimensional range of severity.

Another design decision that hinders the interpretation of the study results was the inclusion of the M + ACT group to control for the additional attention given to the M + MPT group. The study samples of 34 per group could detect an effect size in the range of 0.7 or 0.8. By contrast, a sample size of 50 per group would be capable of detecting an effect size as low as 0.55. The inclusion of the third study group all but guaranteed a finding of no difference between groups.

The findings of this study, which are consistent with the MTA study, may be somewhat discouraging to those who believe that medication combined with cognitive-behavioural interventions is inherently better than medication alone. The study design and measures presented in this report were unlikely to show a difference between groups because the large effect size of methylphenidate made it difficult to detect additive effects. One of the important contributions of this study is that it adds to the scant literature on the long term efficacy of stimulants in children with ADHD. Missing from this report is information on attrition, dosing, and adverse effects. Perhaps these findings will be presented in a separate report. Another clinical implication not stated in the report is the appropriateness of considering periodic withdrawal of stimulant medication to confirm ongoing need for treatment.

Lawrence Scahill, MSN, PhD
Associate Professor of Nursing & Child Psychiatry, Yale University, CT, USA


For correspondence: Dr Abikoff, NYU Child Study Centre, 215 Lexington Avenue, 13th Floor, New York, NY 10016, USA

Sources of funding: NIMH grant.

www.ebmentalhealth.com